“Sincere Religious Belief” is an Evolving Standard for Psychedelic Churches
A potential expansion of the religious use of psychedelic substances
Psychedelics and Trademark: INTA 2025 Annual Meeting in San Diego!
I am thrilled to share that I will be moderating a Table Topic on the impact of psychedelics legalization on trademark law at the International Trademark Association’s (INTA) 2025 Annual Meeting in San Diego! The session will take place Tuesday, May 20, 2025, from 8:00 AM – 10:00 AM (PST). With the increasing legalization of
Ninth Circuit Issues Disappointing Ruling on Terminally Ill Patients and Psilocybin
Ninth Circuit sides with DEA on doctors petition to seek waiver under Right to Try laws
Oregon Psilocybin: State of the State (2024)
The end of 2024 marks two years in the books for the Oregon Psilocybin Services (OPS) program. It has been a long road: in my year-end 2023 post, I explained that the program was incubated on a protracted, two-year runway prior to launch. This mean we are four years along, with two years of live
Updates on MDMA, Ketamine, and the Future of Psychedelic Therapies
Over the last few weeks, the federal government has taken a number of actions that signal a dark future for psychedelic therapies. Today we’ll take a quick look at what’s happened, and what may happen in the future. FDA gives thumbs down to MDMA Earlier in August, the FDA opted not to approve Lykos Therapeutics’
Happy 4th of July!
Happy 4th of July from all of us here at the Psychedelics Law Blog! We hope you have a fun, safe and not-too-hot holiday with family and friends. We will be back soon with our regular programming.
Oregon Psilocybin: Preparing for the End of Local Ownership Rules
Oregon’s rule limiting the non-resident ownership of licensed psilocybin businesses sunsets on December 31, 2024. That’s a little over six months away. Six months is not that long, especially in the context of getting to know an industry or a business, and putting a thoughtful deal together– one that will generate reasonable returns for an
FDA Grants Priority Status to New MDMA Drug
A new age for psychedelics We are on the verge of a psychedelic renaissance, with the Food and Drug Administration (FDA) accepting a new drug application for midmafetamine (MDMA) in February of this year. MDMA the active ingredient in the common party drug “ecstasy” or “molly”. If approved, the drug would be used to treat
Psychedelics and the Military: An Unlikely Alliance
Despite decades of stigma and legal barriers, recent years have brought a profound shift in attitudes towards psychedelics. Driven by scientific inquiry and a growing recognition of their potential therapeutic benefits, the benefits of psychedelics are being explored. In this blog post, we explore the impact of an unexpected catalyst driving progress in psychedelics research–
Arizona’s Psilocybin Legislation
Psilocybin’s therapeutic renaissance Once relegated to the realm of recreational drug use, psilocybin is now at the forefront of a discussion on the potential therapeutic benefits of psychedelics. Arizona is the latest state to take up the discourse: its proposed Senate Bill 1570 (SB 1570) would establish licensed psychedelic-assisted therapy centers, and advance scientific research